[Second look operation from the current viewpoint].
Tumor reduction or elimination during primary surgery is the most important goal to aim at. Platinum-containing poly-chemotherapies led to an increase in remissions. However, highly advanced technologies (computed tomography, ultrasonography, nuclear magnetic resonance) and combined analysis of tumor markers are not sensitive enough to evaluate tumor-free status. A false-positive rate up to 33% at the time of second-look surgery was assessed in patients in clinical complete remission. Therapeutic second-look surgery with the purpose of tumor reduction is not capable to prolong the patient's survival time. Therefore, second-look surgery is limited to a diagnostic procedure, resulting in an objective assessment of newly developed therapy strategies.
Janisch
H
H
II. Universitäts-Frauenklinik, Wien, Osterreich.
D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D010051:Ovarian Neoplasms / Q000401:mortality / Q000601:surgery*; D011183:Postoperative Complications / Q000401:mortality / Q000601:surgery*; D012086:Reoperation; D015996:Survival Rate
Die "Second-look"-Operation aus heutiger Sicht.